Classification and Evaluation of the Overweight Patient

2003 ◽  
pp. 16-47 ◽  
Keyword(s):  
Overweight Patient

Mefloquine adverse effects with atypical facial lesions in an overweight patient

2010 ◽  
Vol 8 (5) ◽  
pp. 318-321 ◽  
Author(s):  
Elodie Descloux ◽  
Frédérique De Monbrison ◽  
Cécile Basselin ◽  
Thierry Vial ◽  
François Peyron
Keyword(s):  
Adverse Effects ◽  
Overweight Patient

Clinical Evaluation of the Overweight Patient

Endocrine ◽  
2000 ◽  
Vol 13 (2) ◽  
pp. 167-186 ◽  
Author(s):  
George A. Bray ◽  
Donna H. Ryan
Keyword(s):  
Clinical Evaluation ◽  
Overweight Patient

Identifying Risk Factors in a Mostly Overweight Patient Population with Coronary Artery Disease

Angiology ◽  
2003 ◽  
Vol 54 (2) ◽  
pp. 181-186 ◽  
Author(s):  
Saim Yologlu ◽  
Alpay Turan Sezgin ◽  
Ramazan Ozdemir ◽  
Nurzen Sezgin ◽  
Cemil Colak ◽  
...  
Keyword(s):  
Risk Factors ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Patient Population ◽  
Overweight Patient ◽  
Artery Disease

Management of the overweight patient with Type 2 diabetes

2003 ◽  
Vol 20 (s4) ◽  
pp. 10-13
Author(s):  
P. Peter ◽  
S. Kumar
Keyword(s):  
Type 2 Diabetes ◽  
Overweight Patient

Inadequate Therapeutic Response to a Recommended Antituberculosis Fixed-Dose Combination Regimen in an Overweight Patient with Mycobacterium bovis Infection

2013 ◽  
Vol 47 (1) ◽  
pp. e4-e4
Author(s):  
Célia Lloret-Linares ◽  
Stéphane Mouly ◽  
Dan-Tranh Hoang-Nguyen ◽  
John Evans ◽  
Laurent Raskine ◽  
...  
Keyword(s):  
Mycobacterium Bovis ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Therapeutic Drug ◽  
Combination Regimen ◽  
Overweight Patient ◽  
Tuberculosis Complex ◽  
Drug Concentrations ◽  
Dose Combination ◽  
Lymph Node Tuberculosis

OBJECTIVE To report a case of an overweight man with lymph node tuberculosis due to Mycobacterium bovis, a part of the Mycobacterium tuberculosis complex, treated with fixed-dose combination (FDC) chemotherapy. CASE REPORT Following guidelines, according to the patient's weight (92 kg), we prescribed the maximum recommended doses of isoniazid-rifampin-pyrazinamide FDC. It led initially to underdosing, with a poor clinical outcome, justifying increased doses and a complex regimen using separate drugs (isoniazid 600 mg, rifampin 1200 mg, and levofloxacin 1000 mg) to achieve therapeutic drug concentrations and clinical response. DISCUSSION Usually recommended doses of FDC chemotherapies may be inappropriate in overweight patients. We discuss here the different factors that may be involved in poor clinical outcomes, particularly the consequences of excess weight on drug metabolism: drug-drug interaction, FDC use, generic formulation use, intestinal malabsorption, and acetylation profile. CONCLUSIONS Therapeutic drug monitoring in overweight patients may be useful in the clinical setting to help clinicians individualize drug therapeutic regimens and optimize drug response, adherence, and safety.

Pharmacological Treatment of the Overweight Patient

2007 ◽  
Vol 59 (2) ◽  
pp. 151-184 ◽  
Author(s):  
George A. Bray ◽  
Frank L. Greenway
Keyword(s):  
Pharmacological Treatment ◽  
Overweight Patient
Sign in / Sign up

Export Citation Format

Share Document